Monoclonal antibodies (mAbs) can be potent and highly specific therapeutics, diagnostics and research reagents.\r\nNonetheless, mAb discovery using current in vivo or in vitro approaches can be costly and time-consuming, with no\r\nguarantee of success. We have established a platform for rapid discovery and optimization of mAbs ex vivo. This DTLacO\r\nplatform derives from a chicken B cell line that has been engineered to enable rapid selection and seamless maturation of\r\nhigh affinity mAbs. We have validated the DTLacO platform by generation of high affinity and specific mAbs to five cell\r\nsurface targets, the receptor tyrosine kinases VEGFR2 and TIE2, the glycoprotein TROP2, the small TNF receptor family\r\nmember FN14, and the G protein-coupled receptor FZD10. mAb discovery is rapid and humanization is straightforward,\r\nestablishing the utility of the DTLacO platform for identification of mAbs for therapeutic and other applications.
Loading....